OrthoPreserve is developing the first anatomically accurate synthetic meniscus implant to restore knee function and preserve joint health for patients after meniscus surgery. Hundreds of thousands of patients each year experience knee pain, mechanical impairment, and joint degeneration after a meniscectomy – the surgical removal of meniscus tissue – yet no FDA-approved meniscus replacements are available. OrthoPreserve’s minimally invasive, surgeon-friendly implant fills this critical treatment gap, aiming to enhance mobility and prevent further knee damage. Backed by FDA Breakthrough Device Designation and strong preclinical results, the company is advancing toward clinical trials with a transformative solution in musculoskeletal care.